CD274 and non-small cell lung carcinoma: Concurrent inhibition of these two inhibitory pathways in a phase 1 study of patients with advanced NSCLC after progression on chemotherapy demonstrated favorable clinical activity, particularly in PD-L1 high tumors [89].